m+Medelevator.RU
← Поиск публикаций
JAAD international · 2026

International expert consensus on transdermal drug delivery technologies in dermatology.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Zhu Jinjin, Li Yan, Wang Xiuli, Xiang Leihong, Röcken Martin, Piguet Vincent, Verma Shyam, Thaçi Diamant, Li Chunying, Chen Xiang, Zhu Mingji, Miao Xiaoping, Wang Honglin, Zhou Cheng, Ding Yan, Xie Jun, Shi Yuling, Goldman Mitchel P, Hao Fei, Mu Qiri, Man Xiaoyong, Chung Wen-Hung, Wang Xue, Xiao Rong, Yu Nan, Chen Aijun, Zhu Jintao, Cui Yong, Ma Lin, Yin Ping, Bu Wenbo, Yang Liu, Li Jun, Gao Xinghua, Tao Juan

Аннотация

BACKGROUND: Transdermal drug delivery technologies (TDDTs) enhance drug absorption and therapeutic outcomes in dermatology, yet standardized, evidence-based recommendations for their clinical application remain lacking.

OBJECTIVE: To provide expert consensus recommendations on the clinical application of TDDTs, with a focus on fractional lasers and microneedles.

METHODS: A multidisciplinary panel of 25 experts systematically reviewed current literature and clinical practices. The consensus was developed using the Grading of Recommendations Assessment, Development and Evaluation framework to assess evidence quality and recommendation strength and the modified Delphi method to achieve expert agreement.

RESULTS: Evidence-based recommendations were formulated for the use of TDDTs in a variety of dermatological conditions, including cutaneous malignancies and precancerous lesions, viral warts, inflammatory and autoimmune skin diseases, and cosmetic indications.

CONCLUSION: Fractional lasers and microneedles are valuable transdermal delivery tools for dermatological therapy. This expert consensus provides practical, evidence-based guidance to support their safe and effective clinical use.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты